Synonym
Dromostanolone propionate; NSC1298; NSC 1298; NSC-1298
IUPAC/Chemical Name
5-alpha-Androstan-3-one, 17-beta-hydroxy-2-alpha-methyl-, propionate
InChi Key
NOTIQUSPUUHHEH-UXOVVSIBSA-N
InChi Code
InChI=1S/C23H36O3/c1-5-21(25)26-20-9-8-17-16-7-6-15-12-19(24)14(2)13-23(15,4)18(16)10-11-22(17,20)3/h14-18,20H,5-13H2,1-4H3/t14-,15+,16+,17+,18+,20+,22+,23+/m1/s1
SMILES Code
C[C@@]12[C@@H](OC(CC)=O)CC[C@@]1([H])[C@]3([H])CC[C@@]4([H])CC([C@H](C)C[C@]4(C)[C@@]3([H])CC2)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
Dromostanolone propionate is a biochemical.
|
Solvent |
mg/mL |
mM |
| Solubility |
| DMF |
30.0 |
83.21 |
| DMSO |
24.0 |
66.57 |
| Ethanol |
2.0 |
5.55 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
360.54
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
TBD
1: Borodi G, Turza A, Bende A. Exploring the Polymorphism of Drostanolone Propionate. Molecules. 2020 Mar 21;25(6):1436. doi: 10.3390/molecules25061436. PMID: 32245263; PMCID: PMC7145311.
2: Seay DG, Bradshaw JD, Nicol NT. Clinical experience with dromostanolone propionate (NSC-12198) in breast carcinoma. Cancer Chemother Rep. 1972 Feb;56(1):89-92. PMID: 5067664.
3: Takeuchi S, Yoshida M. [Clinical study of dromostanolone propionate for mastopathy--with special reference to screening of breast cancer]. Saishin Igaku. 1967 May;22(5):1049-54. Japanese. PMID: 5630583.
4: Nomura Y, Hattori T, Abe Y, Iguchi K. [Long-term combined administration of dromostanolone propionate (Mastisol) and cyclophosphamide (Endoxan) for advanced breast cancer after surgical hormone therapy]. Gan No Rinsho. 1971 Dec;17(12):899-904. Japanese. PMID: 5172404.
5: Fujita H, Teller MN, Green S, Kreis W. Effects of 5-fluorouracil and 2 alpha- methyldihydrotestosterone propionate on the growth of human breast carcinoma MCF-7 in vitro. Eur J Cancer Clin Oncol. 1983 Sep;19(9):1231-7. doi: 10.1016/0277-5379(83)90200-6. PMID: 6688585.
6: Kraus SL, Emmert S, Schön MP, Haenssle HA. The dark side of beauty: acne fulminans induced by anabolic steroids in a male bodybuilder. Arch Dermatol. 2012 Oct;148(10):1210-2. doi: 10.1001/archdermatol.2012.855. PMID: 23069972.
7: Marinov L, Tsekova V, Koĭnov K, Velikova M, Micheva D. Drostanolon-propionat (masteril) pri diseminiraniia rak na mlechna ta zhleza u zhenata. Neposredstveni rezultati [Drostanolone propionate (masteril) in disseminated breast cancer in women. Immediate results]. Khirurgiia (Sofiia). 1987;40(6):80-6. Bulgarian. PMID: 2830431.
8: Teller MN, Stock CC, Bowie M, Chou TC, Budinger JM. Therapy of 7,12-dimethylbenz(a)anthracene-induced rat mammary carcinomas with combinations of 5-fluorouracil and 2 alpha-methyldihydrotestosterone propionate. Cancer Res. 1982 Nov;42(11):4408-12. PMID: 6812946.
9: Pieńkowska F, Paszko Z, Padzik H, Dziadek T. Porównanie skutków endokrynnej terapii u kobiet chorych na raka sutka z obecnościa receptora estrogenowego w tkance nowotworowej [Relationship between the effects of endocrinological treatment of breast cancer and the presence of estrogen receptor in the cancer tissue]. Nowotwory. 1980 Jan-Mar;30(1):25-35. Polish. PMID: 6893078.
10: Clavel B, Cappelaere JP, Guerin J, Klein T, Pommatau E, Berlie J. Le traitement des cancers du sein dépassés chez la femme ménopausée. Etude comparative de l'hormonothérapie, de la chimiothérapie et de l'hormono- chimiothérapie [Management of advanced breast cancer in post-menopausal women. A comparative trial of hormonal therapy, chemotherapy, and a combination of both]. Sem Hop. 1982 Sep 23;58(34):1919-23. French. PMID: 6293073.
